Navigation Links
Neurogen Proprietary Insomnia Compound Data Presented at American,Psychiatric Association Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--May 23, 2007 - Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 and Phase 2a clinical studies for NG2-73, the Company's lead compound for the treatment of insomnia, were presented today at the American Psychiatric Association (APA) annual meeting in San Diego. Two Phase 2b clinical studies with NG2-73 in chronic insomnia patients are currently being conducted by the Company. Data presented at the APA meeting include the following abstracts:

--NG2-73, a Novel GABA(A) Partial Agonist, Rapidly Induced Sleep in a Transient Insomnia Study (Phase 2a)

NG2-73 is a partial GABA(A) agonist with preference for receptors containing the (alpha)3 subunit. Preclinical studies suggest that this compound has sedative hypnotic effects, supporting development as a potential treatment for insomnia.

This double-blind, placebo-controlled, randomized, multi-center study was designed to determine the effects of 1,3,10 and 20mg of NG2-73 compared to placebo on sleep onset as measured by Latency to Persistent Sleep (LPS) in healthy adults. The study design incorporated a single-night, polysomnography (PSG) model of transient insomnia using both first night sleep laboratory adaptation and "phase-advance" effects. Subjects were dosed in the sleep laboratory 2.5 hours prior to median habitual bedtime. "Lights off" and PSG recording started 30 minutes later. Safety was monitored by adverse event recording, physical exams, vital signs, electrocardiogram (ECG) and clinical laboratory tests. 369 healthy subjects aged 24-63 with no self-reported sleep disorders were enrolled.

LPS was statistically significantly reduced, compared to placebo, at all doses of NG2-73, and demonstrated a dose-response relationship. The mean times for LPS were 30.8 minutes for the Placebo group, and 17.8, 10.6, 7.8, and 6.6 minutes for the 1, 3, 10, and 20 mg NG2-73 groups, resp
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
2. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
10. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:7/31/2014)... MOUNTAIN VIEW, Calif., July 31, 2014 IRIDEX Corporation ... the second quarter and six months ended June 28, 2014.  ... quarter of 2014, up 15% from $9.2 million in the ... the first quarter of 2014. Revenues for the first six ... million in the first six months of last year. ...
(Date:7/31/2014)... 31, 2014  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, 2014 at ... Conference, New York, NY Thursday, September ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:7/31/2014)... 2014 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... the development of its lead molecule, Anatabine Citrate, in ... selected Quotient Clinical, The Translational Pharmaceutics Company, based in ... run its early development programs. The Company ... the end of the third quarter with the Medicines ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
(Date:8/2/2014)... When the Black Hat conventioneers descend on Las Vegas ... can be always counted on, plenty of FUD will be ... doubt. The run-up has already made its share of ... on July 31st about how hackers could use a ... infect a system with malware, completely undetected, by leveraging the ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Cannabis use among ... teens aged 14 to 17 having used marijuana at least ... With their slogan “Say ‘No’ to Drugs, Say ‘Yes to ... reaching out to youth this summer with factual information about ... past six months, Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ ...
(Date:8/1/2014)... a central role in regulating appetite and whole-body metabolism. ... brain,s control of food intake and body weight, but ... been unclear. A new study in the ... activity in a type of neuron known as pro-opiomelanocortin ... high-fat diet. Sabrina Diano and colleagues at Yale ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- The U.S. Food ... a new drug, Jardiance, to help fight type 2 ... or added to existing treatment regimens to control blood ... Curtis Rosebraugh, director of the Office of Drug Evaluation ... Research, said in an agency statement. The FDA ...
(Date:8/1/2014)... Summer is here, and with it comes ... summer, and they can be a pain for dogs. Animal ... all their customers get rid of ticks and prevent them ... in the summer, which is why they are so active ... and woodland areas and carry a number of diseases, including ...
Breaking Medicine News(10 mins):Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 2Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 3Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 4Health News:Black Hat USA 2014 Will Again Stress Need for Security Basics with Glimpse of What May Lie Ahead 5Health News:Addressing a Serious Issue Affecting German Teens 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:Tis the Season for Tick Prevention 2
... University of New Hampshire finds that U.S. children are routinely ... previously recognized, with nearly half experiencing a physical assault in ... abuse and crime than do adults," said David Finkelhor, director ... study director. "If life were this dangerous for ordinary grown-ups, ...
... BANGKOK, Oct. 6 As thousands of experts around ... health and nutrition at the International Congress of Nutrition ... and Mars, Incorporated are acknowledging the important impact of ... Science - Flavanols and Sustainability," scientists will present evidence ...
... Los Angeles back surgeon, Dr. Rezaian of the California Orthopedic ... Spinal Stenosis . Open back surgery used to be ... pinching nerves, however, recent medical advances have given patients requiring ... of hope. Doctors have pioneered a new laser Spinal Stenosis ...
... ANGELES, Oct. 6 The Renaissance Laser and Vein Institute offers ... stretch marks and sagging skin like never before. Thanks to recent ... skin care lasers in the dermatological and cosmetic skin care world. ... is the Titan Procedure . The Titan laser ...
... Pelosi and the Democratic Women,s Working Group joined leaders from women,s ... discuss how women stand to gain the most ... face discrimination in both coverage and cost if health reform fails. ... , On Why Health Insurance Reform is Essential for ...
... D.D.S., who practices general dentistry in Flint, Mich., was inducted ... during a meeting of the ADA House of Delegates in ... presidency in October 2010 and will lead the more than ... Gist will be the ADA,s first African-American president. , Dr. ...
Cached Medicine News:Health News:New study finds high rates of childhood exposure to violence and abuse in US 2Health News:Cocoa Research Finds a Place in the Global Health Dialogue 2Health News:Cocoa Research Finds a Place in the Global Health Dialogue 3Health News:Cocoa Research Finds a Place in the Global Health Dialogue 4Health News:Cocoa Research Finds a Place in the Global Health Dialogue 5Health News:California Surgeon (laserbacksurgery.com) Pioneers Exciting Alternative to Traditional Spinal Stenosis Treatment 2Health News:Southern California Renaissance Laser and Vein Institute (laserandveinclinic.com) Offers Cutting Edge New Titan Procedure 2Health News:Pelosi: Health Insurance Reform Essential for Women 2Health News:Pelosi: Health Insurance Reform Essential for Women 3Health News:Pelosi: Health Insurance Reform Essential for Women 4Health News:Pelosi: Health Insurance Reform Essential for Women 5Health News:Michigan Dentist Chosen President-Elect of the American Dental Association 2
... Injection is supplied in an isotonic solution ... intravenous administration. Each milliliter contains 37 megabecquerels ... calibration time, made isotonic with 9 milligrams ... benzyl alcohol. The pH is adjusted to ...
... single-detector system offers general purpose ... for gurneys and wheelchairs. This ... versatile open gantry, caudal/cephalic detector ... for SPECT and whole body ...
Stainless steel lancet blade in stainless steel....
Sharp diamond shaped double blade in stainless steel....
Medicine Products: